Jazz Sues Avadel to Block Sales of Once-Nightly Narcolepsy Drug

Jazzsaid Avadel’s once-nightly narcolepsy drug infringes five patents related to the active ingredient in Jazz’s twice-nightly Xyrem.

• Jazz is seeking a court order blocking sales of Avadel’s proposed drug and blocking Avadel from practicing any methods covered by patents, and cash compensation if Avadel has “committed any acts” related to compositions or methods in patents, according to complaint filed Wednesday in federal court in Wilmington, Delaware
• Avadel said during Monday earnings call it has “accelerated” its launch for its proposed drug, known as FT218, complaint says
• Patents cover methods of use and administration of sodium oxybate, complaint says ...